PBD

ADC Therapeutics to Participate in Guggenheim Oncology Conference

Retrieved on: 
Wednesday, February 2, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, EST, Webcast, B-cell lymphoma, View, Patient, Therapy, Investor, ADC, Twitter, Diffuse large B-cell lymphoma, Technology, Cancer, Lymphatic system, Hodgkin lymphoma, Company, Doctor of Philosophy, FDA, PBD, Event, NYSE, LinkedIn, Conference, Control, Fine chemical, Camisole, San Francisco Bay Area

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com .

Key Points: 
  • A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com .
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).
  • ADC Therapeutics CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022

Retrieved on: 
Thursday, January 20, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Control, Webcast, Patient, Technology, LinkedIn, NYSE, Hodgkin lymphoma, Lymphatic system, Investor, Diffuse large B-cell lymphoma, Research and development, View, B-cell lymphoma, Therapy, Company, ADC, Doctor of Philosophy, MD, Cancer, PBD, Twitter, FDA, Event, Senior, Fine chemical, Camisole, San Francisco Bay Area

A live webcast will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com.

Key Points: 
  • A live webcast will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com.
  • The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
  • In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

Retrieved on: 
Tuesday, January 18, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Control, U.S. Securities and Exchange Commission, Mitsubishi Tanabe Pharma, Patient, Technology, Research, Forward-looking statement, Sutro Biopharma, Distortion, Lymphoma, LinkedIn, Anti-CD19 immunotoxin, EMA, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Enzyme, NYSE, Adult, Hodgkin lymphoma, DNA, Lymphatic system, Review, Diffuse large B-cell lymphoma, DNA repair, MAA, B-cell lymphoma, Therapy, Company, ADC, Quality of life, Orphan drug, Genetics, Lymphoid leukemia, Advanced Therapy Medicinal Product, Doctor of Philosophy, Induced cell cycle arrest, Cancer, Geography, Food, CHMP, PBD, Twitter, FDA, DLBCL, Fine chemical, Pharmaceutical industry, Camisole, San Francisco Bay Area, ZYNLONTA® (loncastuximab tesirine-lpyl), ADC Therapeutics, ZYNLONTA® (LONCASTUXIMAB TESIRINE-LPYL), ADC THERAPEUTICS

ADC Therapeutics will also receive royalties ranging in percentage from the high teens to the low twenties based on net sales of the product in Japan.

Key Points: 
  • ADC Therapeutics will also receive royalties ranging in percentage from the high teens to the low twenties based on net sales of the product in Japan.
  • "MTPC is delighted to collaborate with ADC Therapeutics, a leader in the field of antibody drug conjugates, to develop and commercialize ZYNLONTA in Japan, said Hiroaki Ueno, PhD, Chief Executive Officer of Mitsubishi Tanabe Pharma Corporation.
  • We will try to improve the quality of life of patients suffering from cancer with the use of ADC Therapeutics novel anti-CD19 ADC, ZYNLONTA.
  • In addition, Overland ADCT BioPharma, a joint venture formed by Overland Pharmaceuticals and ADC Therapeutics, is working to develop and commercialize ZYNLONTA in greater China and Singapore.

Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences

Retrieved on: 
Monday, January 10, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Clinical trial, PBD, Safety, Breast cancer, HER2, DNA, ADC, Control, Cancer, Patient, Index (publishing), Anticoagulant, Fosun International, IND, Therapy, Research, Fosun Pharma, MTD, Anti-CD19 immunotoxin, VP, Celltrion, Therapeutic index, LCB, KOSDAQ, Achievement, Learning, Neoplasm, Biotechnology, Fine chemical, Pharmaceutical industry

The agreement provides Iksuda with exclusive world-wide rights (excluding Greater China and South Korea) to LCBs Her2 ADC programme, LCB14.

Key Points: 
  • The agreement provides Iksuda with exclusive world-wide rights (excluding Greater China and South Korea) to LCBs Her2 ADC programme, LCB14.
  • Iksuda anticipates that LCB14, now designated IKS014, will enter a phase 1 clinical trial programme in the US during Q3 2022.
  • This agreement with LCB allows Iksuda to further expand its clinical development pipeline.
  • The Companys IKS03 programme, a best-in-class CD19-targeting ADC, is also expected to enter phase 1 clinical trials in H1 2022.

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Tuesday, November 9, 2021
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, ADC, View, Cancer, Therapy, Investor, Diffuse large B-cell lymphoma, EST, B-cell lymphoma, Doctor of Philosophy, Technology, PBD, Hodgkin lymphoma, GMT, Lymphatic system, Twitter, Conference, Company, Event, LinkedIn, Control, NYSE, Webcast, Patient, FDA, Pharmaceutical industry, Fine chemical

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com .

Key Points: 
  • A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com .
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).
  • ADC Therapeutics CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q3 2021 Financial Results and Highlights Operational Progress

Retrieved on: 
Thursday, November 4, 2021
Safety, VIVA, University, China, NIH, NIA, Canadian International Council, PBD, Partnership, Patient, Alzheimer's Research & Therapy, Simcere Pharmaceutical, ADCS, Brain, Environmental Molecular Sciences Laboratory, National, Patent, Company, CEO, Hoffmann, AD, International Journal of Molecular Sciences, National Institute, API, Research, Therapy, Alzheimer's Disease Cooperative Study, Journal, De Vijverberg, Euronext Amsterdam, National Institute on Aging, Pharmaceutical industry, Film, Air cargo

"Throughout the third quarter, we made significant progress towards filling the gap of safe, widely available effective disease-modifying therapies in Alzheimer's disease.

Key Points: 
  • "Throughout the third quarter, we made significant progress towards filling the gap of safe, widely available effective disease-modifying therapies in Alzheimer's disease.
  • VIVIAD remains on track for an interim safety readout in mid-22 and Vivoryon continues to anticipate final data in the second half of 2023.
  • Research and development expenses incurred for the nine months ended September 30, 2021 increased over the corresponding period in 2020 by EUR 3.6 million.
  • General and administrative expenses increased by EUR 1.2 million for the nine months ended September 30, 2021.

ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®

Retrieved on: 
Friday, October 29, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, B-cell lymphoma, Anemia, Control, Disease, European Medicines Agency, Twitter, PBD, NOS, Nausea, Lymphoid leukemia, Therapy, Neutropenia, Doctor of Philosophy, Enzyme, Rash, Diffuse large B-cell lymphoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, View, Advanced Therapy Medicinal Product, Food, Induced cell cycle arrest, DNA repair, Lymphoma, European Commission, Hyperglycemia, Company, Genetics, MAA, DLBCL, ADC, EMA, Marketing Authorisation Application, Marketing, NYSE, Lymphatic system, ORR, Distortion, Thrombocytopenia, Royal commission, Fatigue, Orphan, Patient, DNA, Technology, LinkedIn, Cancer, Hodgkin lymphoma, Edema, FDA, CHMP, Adult, Gamma-glutamyltransferase, Lists of diseases, Vaccine, Pharmaceutical industry, ZYNLONTA®, ADC Therapeutics, ZYNLONTA®, ADC THERAPEUTICS

Validation of the application enables the evaluation process by the EMAs Committee for Medicinal Products for Human Use (CHMP) to begin.

Key Points: 
  • Validation of the application enables the evaluation process by the EMAs Committee for Medicinal Products for Human Use (CHMP) to begin.
  • This is a significant step forward in our commitment to making ZYNLONTA available to as many patients as may benefit.
  • In September 2021, the European Commission granted Orphan Drug Designation to ZYNLONTA for the treatment of DLBCL.
  • In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021

Retrieved on: 
Wednesday, October 27, 2021
Biotechnology, FDA, Health, Clinical Trials, Oncology, Diffuse large B-cell lymphoma, Technology, LinkedIn, Cancer, Control, Hodgkin lymphoma, Twitter, PBD, ADC, Patient, Investor, FDA, View, NYSE, Lymphatic system, B-cell lymphoma, Company, EDT, Therapy, Pharmaceutical industry, Fine chemical

A live webcast of the presentation will be available under Events and Presentations in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .

Key Points: 
  • A live webcast of the presentation will be available under Events and Presentations in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).
  • In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland, and has operations in London, the San Francisco Bay Area and New Jersey.

SIBA: Majority of the public call for the Government NOT to increase taxes on small breweries at the Budget

Retrieved on: 
Wednesday, October 20, 2021
COVID-19, HGV, Beer, SIBA, Society of Independent Brewers, Government, Industry, Anxiety, PBD, Ageing, CO2, Society, National Insurance, British Polling Council, Risk, Chancellor, Savanta ComRes, Growth, Progressive beer duty, Uncertainty, Tax, SBR, Online gambling

This includes 57% of Conservative voters, who clearly feel that the Chancellor should back not burden small breweries as they emerge from the pandemic.

Key Points: 
  • This includes 57% of Conservative voters, who clearly feel that the Chancellor should back not burden small breweries as they emerge from the pandemic.
  • An additional tax increase on small breweries will put the international success story of this industry in danger.
  • We have been saying for some time that this Budget should back not burden small breweries and it's great that the public and Conservative voters think so too.
  • "We urge the Chancellor to listen to small breweries, and the public, and help small breweries across the country to thrive."

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma

Retrieved on: 
Wednesday, September 29, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, CD19, DNA, FDA, U.S. Securities and Exchange Commission, DLBCL, Patient, Multimedia, Diffuse large B-cell lymphoma, Distortion, Cancer, Population, Securities and Exchange Commission (Philippines), LinkedIn, Adult, Lymphoid leukemia, Twitter, Lymphoma, Medicine, PBD, Company, Induced cell cycle arrest, Control, Genetics, Technology, ADC, Lymphatic system, Research, Forward-looking statement, Safety, B-cell lymphoma, Follicular lymphoma, Doctor of Philosophy, NYSE, DNA repair, Enzyme, NOS, Fine chemical, Pharmaceutical industry, Vaccine, ZYNLONTA, Overland ADCT BioPharma, ADC Therapeutics, Overland Pharmaceuticals, ZYNLONTA, OVERLAND ADCT BIOPHARMA, ADC THERAPEUTICS, OVERLAND PHARMACEUTICALS

Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the first patient has been dosed with ZYNLONTAin a pivotal Phase 2 clinical trial in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in China.

Key Points: 
  • Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the first patient has been dosed with ZYNLONTAin a pivotal Phase 2 clinical trial in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in China.
  • This local pivotal study mirrors ADC Therapeutics ongoing global pivotal Phase 2 clinical trial of ZYNLONTA and its results are intended to support the potential registration of ZYNLONTA in China.
  • Dosing the first patient in this pivotal trial is a key milestone for Overland ADCT BioPharma as we collaborate to expand the clinical reach of ZYNLONTA in greater China and Singapore, said Eric Koo, Chief Executive Officer of Overland ADCT BioPharma.
  • The China Phase 2, multi-center, open-label, single-arm study will evaluate the efficacy and safety of ZYNLONTA used as monotherapy in patients with r/r DLBCL.